References: Binder S, Corrigan JD, Langlois JA. The public health approach to traumatic brain injury: an overview of CDC's research and programs. J Head Trauma Rehabil. 2005;20(3):189-195.
Gupta R, Sen N. Traumatic brain injury: a risk factor for neurodegenerative diseases. Rev Neurosci. 2016;27(1):93-100.
Siedler DG, Chuah MI, Kirkcaldie MT, Vickers JC, King AE. Diffuse axonal injury in brain trauma: insights from alterations in neurofilaments. Front Cell Neurosci. 2014;8:429.
Vosler PS, Sun D, Wang S, et al. Calcium dysregulation induces apoptosis-inducing factor release: cross-talk between PARP-1- and calpain-signaling pathways. Exp Neurol. 2009;218(2):213-220.
Yildiz-Unal A, Korulu S, Karabay A. Neuroprotective strategies against calpain-mediated neurodegeneration. Neuropsychiatr Dis Treat. 2015;11:297-310.
Anagli J, Han Y, Stewart L, et al. A novel calpastatin-based inhibitor improves postischemic neurological recovery. Biochem Biophys Res Commun. 2009;385(1):94-99.
Koumura A, Nonaka Y, Hyakkoku K, et al. A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neuroscience. 2008;157(2):309-318.
Kobeissy FH, Liu MC, Yang Z, et al. Degradation of betaII-Spectrin protein by Calpain-2 and Caspase-3 under neurotoxic and traumatic brain injury conditions. Mol Neurobiol. 2015;52(1):696-709.
Liu S, Yin F, Zhang J, Qian Y. The role of calpains in traumatic brain injury. Brain Inj. 2014;28(2):133-137.
Cagmat EB, Guingab-Cagmat JD, Vakulenko AV, Hayes RL, Anagli J. Potential Use of Calpain Inhibitors as Brain Injury Therapy. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. F. H. Kobeissy. Boca Raton (FL). 2015.
Siklos M, BenAissa M, Thatcher GR. Cysteine proteases as therapeutic targets: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm Sin B. 2015;5(6):506-519.
Thompson SN, Carrico KM, Mustafa AG, Bains M, Hall ED. A pharmacological analysis of the neuroprotective efficacy of the brain- and cell-permeable calpain inhibitor MDL-28170 in the mouse controlled cortical impact traumatic brain injury model. J Neurotrauma. 2010;27(12):2233-2243.
Bains M, Cebak JE, Gilmer LK, et al. Pharmacological analysis of the cortical neuronal cytoskeletal protective efficacy of the calpain inhibitor SNJ-1945 in a mouse traumatic brain injury model. J Neurochem. 2013;125(1):125-132.
Schoch KM, von Reyn CR, Bian J, Telling GC, Meaney DF, Saatman KE. Brain injury-induced proteolysis is reduced in a novel calpastatin-overexpressing transgenic mouse. J Neurochem. 2013;125(6):909-920.
Donkor IO. Calpain inhibitors: a survey of compounds reported in the patent and scientific literature. Expert Opin Ther Pat. 2011;21(5):601-636.
Baudry M, Bi X. Calpain-1 and Calpain-2: the Yin and Yang of synaptic plasticity and neurodegeneration. Trends Neurosci. 2016;39(4):235-245.
Wang Y, Briz V, Chishti A, Bi X, Baudry M. Distinct roles for mu-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration. J Neurosci. 2013;33(48):18880-18892.
Wang Y, Zhu G, Briz V, Hsu YT, Bi X, Baudry M. A molecular brake controls the magnitude of long-term potentiation. Nat Commun. 2014;5:3051.
Li Z, Ortega-Vilain AC, Patil GS, et al. Novel peptidyl alpha-keto amide inhibitors of calpains and other cysteine proteases. J Med Chem. 1996;39(20):4089-4098.
Liu Y, Wang Y, Zhu G, Sun J, Bi X, Baudry M. A calpain-2 selective inhibitor enhances learning & memory by prolonging ERK activation. Neuropharmacology. 2016;105:471-477.
Wang Y, Lopez D, Davey PG, et al. Calpain-1 and calpain-2 play opposite roles in retinal ganglion cell degeneration induced by retinal ischemia/reperfusion injury. Neurobiol Dis. 2016;93:121-128.
Wang Y, Liu Y, Lopez D, et al. Protection against TBI-induced neuronal death with post-treatment with a selective Calpain-2 inhibitor in mice. J Neurotrauma. 2018;35(1):105-117.
Molecular Operating Environment (MOE) v. 2013.08 (Chemical Computing Group Inc., M., QC, Canada). 2016.
Best RB, Zhu X, Shim J, et al. Optimization of the additive CHARMM all-atom protein force field targeting improved sampling of the backbone phi, psi and side-chain chi(1) and chi(2) dihedral angles. J Chem Theory Comput. 2012;8(9):3257-3273.
Chatterjee P, Botello-Smith WM, Zhang H, et al. Can relative binding free energy predict selectivity of reversible covalent inhibitors? J Am Chem Soc. 2017;139(49):17945-17952.
Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29(11):1859-1865.
Jorgensen W, Chandrasekhar J, Madura J, Impey R, Klein M. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926-935.
Phillips JC, Braun R, Wang W, et al. Scalable molecular dynamics with NAMD. J Comput Chem. 2005;26(16):1781-1802.
Adelman S, Garrison B. Generalized Langevin theory for gas/solid processes: dynamical solid models. J Chem Phys. 1976;65:3751-3761.
Hess B, Kutzner C, van der Spoel D, Lindahl E. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput. 2008;4(3):435-447.
Sasaki T, Kikuchi T, Yumoto N, Yoshimura N, Murachi T. Comparative specificity and kinetic studies on porcine calpain I and calpain II with naturally occurring peptides and synthetic fluorogenic substrates. J Biol Chem. 1984;259(20):12489-12494.
Elce JS, Hegadorn C, Gauthier S, Vince JW, Davies PL. Recombinant calpain II: improved expression systems and production of a C105A active-site mutant for crystallography. Protein Eng. 1995;8(8):843-848.
Simonson L, Baudry M, Siman R, Lynch G. Regional distribution of soluble calcium activated proteinase activity in neonatal and adult rat brain. Brain Res. 1985;327(1-2):153-159.
Harding JJ. Immune checkpoint blockade in advanced hepatocellular carcinoma: an update and critical review of ongoing clinical trials. Future Oncol. 2018;14(22):2293-2302.
Alexander SPH, Kelly E, Mathie AA, et al. The concise guide to PHARMACOLOGY 2023/24: introduction and other protein targets. Br J Pharmacol. 2023;180(S2):S1-S22.
Wang Y, Liu Y, Yahya E, Quach D, Bi X, Baudry M. Calpain-2 activation in mouse hippocampus plays a critical role in seizure-induced neuropathology. Neurobiol Dis. 2021;147:105149.
Harbeson SL, Abelleira SM, Akiyama A, et al. Stereospecific synthesis of peptidyl alpha-keto amides as inhibitors of calpain. J Med Chem. 1994;37(18):2918-2929.
Kling A, Jantos K, Mack H, et al. Discovery of novel and highly selective inhibitors of Calpain for the treatment of Alzheimer's disease: 2-(3-phenyl-1H-pyrazol-1-yl)-nicotinamides. J Med Chem. 2017;60(16):7123-7138.
Wang Y, Liu Y, Bi X, Baudry M. Calpain-1 and Calpain-2 in the brain: new evidence for a critical role of Calpain-2 in neuronal death. Cell. 2020a;9(12), 2698.
Wang Y, Liu Y, Nham A, et al. Calpain-2 as a therapeutic target in repeated concussion-induced neuropathy and behavioral impairment. Sci Adv. 2020b;6(27), eaba5547e.
Alluri H, Wiggins-Dohlvik K, Davis ML, Huang JH, Tharakan B. Blood-brain barrier dysfunction following traumatic brain injury. Metab Brain Dis. 2015;30(5):1093-1104.
Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31.
Xu J, Wang H, Ding K, et al. Inhibition of cathepsin S produces neuroprotective effects after traumatic brain injury in mice. Mediat Inflamm. 2013;2013:187873.
Reinheckel T, Deussing J, Roth W, Peters C. Towards specific functions of lysosomal cysteine peptidases: phenotypes of mice deficient for cathepsin B or cathepsin L. Biol Chem. 2001;382(5):735-741.
Jantos K, Kling A, Mack H, et al. Discovery of ABT-957: 1-Benzyl-5-oxopyrrolidine-2-carboxamides as selective calpain inhibitors with enhanced metabolic stability. Bioorg Med Chem Lett. 2019;29(15):1968-1973.
Lon HK, Mendonca N, Goss S, et al. Pharmacokinetics, safety, tolerability, and pharmacodynamics of Alicapistat, a selective inhibitor of human Calpains 1 and 2 for the treatment of Alzheimer disease: an overview of phase 1 studies. Clin Pharmacol Drug Dev. 2019;8(3):290-303.
No Comments.